Equities research analysts forecast that Pfizer Inc. (NYSE:PFE) will announce sales of $13.73 billion for the current quarter, according to Zacks. Two analysts have provided estimates for Pfizer’s earnings, with the highest sales estimate coming in at $13.77 billion and the lowest estimate coming in at $13.69 billion. Pfizer posted sales of $13.70 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 0.2%. The company is expected to issue its next earnings report on Tuesday, January 29th.
On average, analysts expect that Pfizer will report full-year sales of $53.40 billion for the current fiscal year, with estimates ranging from $53.36 billion to $53.44 billion. For the next fiscal year, analysts forecast that the company will post sales of $53.93 billion, with estimates ranging from $53.66 billion to $54.16 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Pfizer.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. The business had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. The company’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.67 earnings per share.
A number of analysts recently weighed in on PFE shares. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Tuesday, October 9th. Morningstar set a $46.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 9th. Independent Research set a $48.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, October 4th. Barclays set a $40.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Friday, October 19th. Finally, Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Thursday, October 4th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $42.67.
In other news, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the transaction, the insider now owns 72,672 shares in the company, valued at approximately $2,979,552. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Pfizer Inc purchased 55,556 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was bought at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the acquisition, the insider now directly owns 21,976,484 shares in the company, valued at $395,576,712. The disclosure for this purchase can be found here. Company insiders own 0.06% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Ballew Advisors Inc acquired a new stake in shares of Pfizer in the first quarter worth approximately $102,000. Fort L.P. acquired a new stake in shares of Pfizer in the second quarter worth approximately $121,000. W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in shares of Pfizer in the first quarter worth approximately $132,000. Braun Bostich & Associates Inc. acquired a new stake in shares of Pfizer in the first quarter worth approximately $139,000. Finally, Smart Portfolios LLC boosted its position in shares of Pfizer by 43.9% in the second quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 68.96% of the company’s stock.
Shares of PFE stock traded up $1.45 on Friday, reaching $44.46. 834,483 shares of the company were exchanged, compared to its average volume of 26,427,534. The stock has a market capitalization of $255.56 billion, a P/E ratio of 16.75, a P/E/G ratio of 2.16 and a beta of 0.88. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41. Pfizer has a 1 year low of $33.20 and a 1 year high of $45.81.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be issued a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.06%. Pfizer’s dividend payout ratio is presently 51.32%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Further Reading: How Do Tariffs Affect Trade Balances?
Get a free copy of the Zacks research report on Pfizer (PFE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.